On November 1, 2022 Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm and CLIA-certified lab, reported that it will exhibit at the Association of Molecular Pathologist (AMP) 2022 Annual Meeting & Expo in Phoenix Arizona from November 3, 2022, through November 5, 2022 (Press release, Sysmex Inostics, NOV 1, 2022, View Source [SID1234622668]). The company will exhibit at booth 701 and take meetings in Expo Hall room seven.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sysmex Inostics will unveil its new website, developed with the award-winning creative agency TRAINA, which echoes Sysmex Inostics’ efforts to deliver intelligent, scientific solutions with a human-centric focus on the boundless potential of every patient.
"As a world-class CLIA lab and liquid biopsy provider, we employ innovative diagnostic tools to fight life shattering diseases. We believe in enhancing every phase of a patient’s journey, from helping bring life-saving drugs to market and expanding treatment options, to giving patients the tools and information they need to live the fullest life possible," said Sysmex Inostics, CEO, Shinichi Sato.
"Our team is committed to changing outcomes for the better. We understand every molecule counts, every decision counts and every patient counts," concluded Sato.
Sysmex Inostics helped pave the way to personal, accurate treatment of devasting diseases through its ultra-sensitive liquid biopsy and biomarker analysis. By empowering actionable molecular discoveries with its next generation sequencing Plasma-Safe-SeqS technology tests and in the past with its venerable OncoBEAM technology, the company has played a significant role in solid tumor cancer and Acute Myeloid Leukemia (AML) discoveries serving the pharmaceutical, clinical, and research communities.
Sysmex Inostics has been active in 2022 with several noteworthy accomplishments:
Partnered with the Foundation of the National Institute of Health (FNIH) & Commenced New Ultra-Sensitive Leukemia Detection Test
In May, Sysmex Inostics partnered with FNIH to discover new modalities to detect and monitor AML Minimal Residual Disease (MRD) which has one of the worst cancer outcomes at a 31 percent 5-year relative survival rate.1
At the same time, Sysmex Inostics began to offer its AML-SEQ CLIA-validated testing service, a focused panel to detect mutations of the three most prevalent genes found in AML. The new test rounds out the company’s offerings with a less expensive test compared to the broader AML-MRD-SEQ for the detection of MRD in 68 regions across 20 genes launched in October 2021.
Launched Head & Neck Cancer CLIA Validated Testing Service
In February, Sysmex Inostics launched its Head & Neck Cancer CLIA-validated testing service, HNSCC sequencing, for cancers that are HPV-negative and driven by mutations in key genes. This test is complementary to the company’s HPV-SEQ service which can identify, quantify, and track HPV 16/18.